The effects of alpha-trinositol on haemodynamic variables and neuropeptide Y levels in a pilot study of hypertensives and healthy volunteers

What Was Tested

This controlled clinical trial paper looks at Neuropeptide Y.

The aim of this study was to examine the effects of D-myo-inositol-1,2,6-trisphosphate (alpha-trinositol) on haemodynamic variables and neuropeptide Y (NPY) levels in hypertensives and healthy volunteers.

Who Took Part

PubMed indexes the participants as adults, men only.

Hypertensives (n = 13) and normotensives (n = 11) were recruited after a screening of cardiovascular risk factors of all men aged 40 living in a well defined area.

How the Study Was Run

The design is described as double-blind, placebo-controlled, crossover and pilot.

Neither the participants nor the staff measuring them knew who was on Neuropeptide Y, so expectations could not easily colour the readings.

Some participants received a placebo instead of Neuropeptide Y, giving a reference point.

In the crossover set-up each of the participants took both Neuropeptide Y and the comparison in turn, acting as their own control.

It is described as a pilot, a small early test of whether a larger Neuropeptide Y study would be practical.

The hypertensives were previously unmedicated.

What Was Measured

Topics PubMed links to this paper include Blood Pressure, Heart Rate, Hemodynamics, Hypertension, Inositol Phosphates, Neuropeptide Y and Pilot Projects.

What This Means in Plain Language

The paper is a double-blind, placebo-controlled and crossover study of Neuropeptide Y.

The abstract goes on to report its results in about 10 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 1994 (Blood pressure), a journal based in England.

More context: the Neuropeptide Y compound page, all human trials.